OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ubrogepant for the treatment of migraine
Martina Curto, Matilde Capi, Fabiola Cipolla, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 755-759
Closed Access | Times Cited: 45
Martina Curto, Matilde Capi, Fabiola Cipolla, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 755-759
Closed Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, et al.
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 6, pp. 627-641
Closed Access | Times Cited: 60
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, et al.
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 6, pp. 627-641
Closed Access | Times Cited: 60
Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions
Yee Jung Kim, Richard D. Granstein
Brain Behavior & Immunity - Health (2021) Vol. 18, pp. 100361-100361
Open Access | Times Cited: 45
Yee Jung Kim, Richard D. Granstein
Brain Behavior & Immunity - Health (2021) Vol. 18, pp. 100361-100361
Open Access | Times Cited: 45
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials
Xinxin Deng, Liying Zhou, Cui Liang, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Xinxin Deng, Liying Zhou, Cui Liang, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Diagnosis and acute management of migraine
Velina Tzankova, Werner J. Becker, Tommy Lik Hang Chan
Canadian Medical Association Journal (2023) Vol. 195, Iss. 4, pp. E153-E158
Open Access | Times Cited: 13
Velina Tzankova, Werner J. Becker, Tommy Lik Hang Chan
Canadian Medical Association Journal (2023) Vol. 195, Iss. 4, pp. E153-E158
Open Access | Times Cited: 13
Real‐world efficacy, tolerability, and safety of ubrogepant
Chia‐Chun Chiang, Karissa N. Arca, Rachel B. Dunn, et al.
Headache The Journal of Head and Face Pain (2021) Vol. 61, Iss. 4, pp. 620-627
Closed Access | Times Cited: 32
Chia‐Chun Chiang, Karissa N. Arca, Rachel B. Dunn, et al.
Headache The Journal of Head and Face Pain (2021) Vol. 61, Iss. 4, pp. 620-627
Closed Access | Times Cited: 32
Comparative Efficacy of Oral Calcitonin-Gene–Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis
Dong Kyoung Ha, Min Ji Kim, Nayoung Han, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 2, pp. 119-132
Closed Access | Times Cited: 25
Dong Kyoung Ha, Min Ji Kim, Nayoung Han, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 2, pp. 119-132
Closed Access | Times Cited: 25
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
Matilde Capi, Valerio De Angelis, Donatella De Bernardini, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 7, pp. 1429-1429
Open Access | Times Cited: 22
Matilde Capi, Valerio De Angelis, Donatella De Bernardini, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 7, pp. 1429-1429
Open Access | Times Cited: 22
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis
Karissa Johnston, Evan Popoff, Alison Deighton, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2021) Vol. 22, Iss. 1, pp. 155-166
Open Access | Times Cited: 21
Karissa Johnston, Evan Popoff, Alison Deighton, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2021) Vol. 22, Iss. 1, pp. 155-166
Open Access | Times Cited: 21
Acute Migraine: Can the New Drugs Clinically Outpace?
Alok Singh, Dhyuti Gupta, Ajaya Kumar Sahoo
SN Comprehensive Clinical Medicine (2020) Vol. 2, Iss. 8, pp. 1132-1138
Closed Access | Times Cited: 23
Alok Singh, Dhyuti Gupta, Ajaya Kumar Sahoo
SN Comprehensive Clinical Medicine (2020) Vol. 2, Iss. 8, pp. 1132-1138
Closed Access | Times Cited: 23
The current state of acute treatment for migraine in adults in the United States
Wade M. Cooper, Erin Doty, Helen Hochstetler, et al.
Postgraduate Medicine (2020) Vol. 132, Iss. 7, pp. 581-589
Open Access | Times Cited: 21
Wade M. Cooper, Erin Doty, Helen Hochstetler, et al.
Postgraduate Medicine (2020) Vol. 132, Iss. 7, pp. 581-589
Open Access | Times Cited: 21
Pharmacological strategies to treat attacks of episodic migraine in adults
Peer Tfelt‐Hansen
Expert Opinion on Pharmacotherapy (2020) Vol. 22, Iss. 3, pp. 305-316
Closed Access | Times Cited: 18
Peer Tfelt‐Hansen
Expert Opinion on Pharmacotherapy (2020) Vol. 22, Iss. 3, pp. 305-316
Closed Access | Times Cited: 18
A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management
Shivang Joshi, Stewart J. Tepper, Sylvia Lucas, et al.
Headache The Journal of Head and Face Pain (2021) Vol. 61, Iss. 6, pp. 838-853
Open Access | Times Cited: 16
Shivang Joshi, Stewart J. Tepper, Sylvia Lucas, et al.
Headache The Journal of Head and Face Pain (2021) Vol. 61, Iss. 6, pp. 838-853
Open Access | Times Cited: 16
Positioning the new drugs for migraine
Silvia Benemei, Enrico Bentivegna, Paolo Martelletti
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 1-3
Open Access | Times Cited: 12
Silvia Benemei, Enrico Bentivegna, Paolo Martelletti
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 1-3
Open Access | Times Cited: 12
Calcitonin gene‑related peptide: A promising bridge between cancer development and cancer‑associated pain in oral squamous cell carcinoma (Review)
Yu Zhang, Chengzhong Lin, Xu Wang, et al.
Oncology Letters (2020) Vol. 20, Iss. 5, pp. 1-1
Open Access | Times Cited: 16
Yu Zhang, Chengzhong Lin, Xu Wang, et al.
Oncology Letters (2020) Vol. 20, Iss. 5, pp. 1-1
Open Access | Times Cited: 16
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
Richard B. Lipton, Janette Contreras‐De Lama, Daniel Serrano, et al.
Neurology and Therapy (2023) Vol. 13, Iss. 1, pp. 69-83
Open Access | Times Cited: 5
Richard B. Lipton, Janette Contreras‐De Lama, Daniel Serrano, et al.
Neurology and Therapy (2023) Vol. 13, Iss. 1, pp. 69-83
Open Access | Times Cited: 5
An Assessment of Sex and Gender Considerations in Migraine Calcitonin Gene Related Peptide Clinical Trials
Melissa O’Brien, Jessica A. J. Dawe
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024), pp. 1-22
Closed Access | Times Cited: 1
Melissa O’Brien, Jessica A. J. Dawe
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024), pp. 1-22
Closed Access | Times Cited: 1
An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies
Abimael González‐Hernández, Miguel Condés‐Lara, Enrique García-Boll, et al.
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 2, pp. 179-199
Closed Access | Times Cited: 9
Abimael González‐Hernández, Miguel Condés‐Lara, Enrique García-Boll, et al.
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 2, pp. 179-199
Closed Access | Times Cited: 9
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
Andrew Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 692-705
Open Access | Times Cited: 9
Andrew Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 692-705
Open Access | Times Cited: 9
Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
Bing Cao, Shanshan Gu, Zhisen Shen, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 3, pp. 297-303
Closed Access | Times Cited: 3
Bing Cao, Shanshan Gu, Zhisen Shen, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 3, pp. 297-303
Closed Access | Times Cited: 3
Unmet needs for migraine
Paolo Martelletti, Martina Curto
Current Medical Research and Opinion (2021) Vol. 37, Iss. 11, pp. 1957-1959
Closed Access | Times Cited: 8
Paolo Martelletti, Martina Curto
Current Medical Research and Opinion (2021) Vol. 37, Iss. 11, pp. 1957-1959
Closed Access | Times Cited: 8
Second-generation gepants in the treatment of migraine – a review of the findings of randomised controlled trials
Marcin Kopka
Aktualności Neurologiczne (2023) Vol. 22, Iss. 4, pp. 180-184
Open Access | Times Cited: 2
Marcin Kopka
Aktualności Neurologiczne (2023) Vol. 22, Iss. 4, pp. 180-184
Open Access | Times Cited: 2
Erenumab for episodic migraine
Abhigyan Datta, Sahil Gupta, Shashi Maryala, et al.
Pain Management (2022) Vol. 12, Iss. 5, pp. 587-594
Closed Access | Times Cited: 4
Abhigyan Datta, Sahil Gupta, Shashi Maryala, et al.
Pain Management (2022) Vol. 12, Iss. 5, pp. 587-594
Closed Access | Times Cited: 4
The Disruption of SARS-CoV-2 RBD/ACE-2 Complex by Ubrogepant Is Mediated by Interface Hydration
Olaposi Idowu Omotuyi, Oyekanmi Nash, Bashiru Olaitan Ajiboye, et al.
(2020)
Open Access | Times Cited: 5
Olaposi Idowu Omotuyi, Oyekanmi Nash, Bashiru Olaitan Ajiboye, et al.
(2020)
Open Access | Times Cited: 5
Migraine with Brainstem Aura Accompanied by Disorders of Consciousness
Sui-yi Xu, Huijuan Li, Jing Huang, et al.
Journal of Pain Research (2021) Vol. Volume 14, pp. 1119-1127
Open Access | Times Cited: 5
Sui-yi Xu, Huijuan Li, Jing Huang, et al.
Journal of Pain Research (2021) Vol. Volume 14, pp. 1119-1127
Open Access | Times Cited: 5
